<DOC>
	<DOCNO>NCT02558270</DOCNO>
	<brief_summary>Inhibition SGLT2 specific inhibitor show reduce renal threshold glucose excretion patient type 2 diabetes mellitus ( T2DM ) control subject lead significant renal glucose loss even presence normal glucose concentration . SGLT2 inhibition canagliflozin induce 24h urinary glucose loss around 70g healthy subject . Recent study indicate fast postprandial condition administration SGLT-2 inhibitor lead increase endogenous ( hepatic ) glucose production ( EGP ) potentially counteract glucose lower potency drug . Dapagliflozin show acutely increase endogenous glucose production ( EGP ) plasma glucagon concentration postabsorptive condition within 2 hour drug ingestion patient ( T2DM ) . Glucagon bind receptor liver activate hepatic gluconeogenesis ( GNG ) glycogenolysis , likely contribute observed increase EGP . So far likely interrelation acute change hepatic glucose metabolism energy turnover contribute increase hepatic glucose production induce SGLT2 inhibition study . It know 80 % oxygen consumption couple ATP synthesis , 7- 10 % use GNG . However , far effect dapagliflozin acute change gluconeogenesis ( GNG ) ATP turnover hepatic tissue time course hormone involve hypoglycaemia counter regulation study .</brief_summary>
	<brief_title>Effects SGLT-2 Inhibition Hepatic Glucose Energy Metabolism</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion diabetic patient : Type 2 diabetes BMI 23 35 kg/m2 Age 18 75 year HbA1c &lt; 7.5 % dietary treatment treatment ! ! ! ! two ! oral ! antidiabetic ! agent ! include ! metformin , ! alphaAglucosidase ! inhibitor , ! sulfonyl ! urea ! ! DPPAIV ! inhibitor . Must give write informed consent able comply study requirement Males female . Aged 18 75 year , inclusive , time informed consent Females : Nonpregnant nonlactating ; surgically sterile ( e.g. , tubal occlusion , hysterectomy , bilateral salpingectomy , bilateral oophorectomy ) , postmenopausal ( defined 12 month spontaneous amenorrhea female &gt; 55 year age , females ≤ 55 year , 12 month spontaneous amenorrhea without alternative medical cause FSH level postmenopausal range laboratory involve ) , abstinent , engage sexual relation childbearing potential , subject use acceptable contraceptive method . Body Mass Index ( BMI ) 23 35 kg/m2 Agree maintain current diet exercise regimen . Agree abstain alcoholic beverage least 48 hour prior clinic visit increase alcohol consumption study Exclusion criterion diabetic patient : smoking pregnancy treatment 2 oral antidiabetic agent treatment insulin / SGLT2 inhibitor regular medication tendency towards claustrophobia metal device magnetic material subject body hazardous NMR investigation [ heart pacemaker , brain ( aneurysm ) clip , nerve stimulators , electrode , ear implant , post coronary bypass graft ( epicardial pace wire ) , penile implant , color contact lens , patch deliver medication skin , coil spring intrauterine device , vascular filter blood clot , orthodontic brace , shuntspinal ventricular , metal implant ( rod , joint , plate , pin , screw , nail , clip ) , embolization coil , metal fragment shrapnel body ] . Severe hepatic insufficiency and/or significant abnormal liver function define aspartate aminotransferase ( AST ) &gt; 3x upper limit normal ( ULN ) and/or alanine aminotransferase ( ALT ) &gt; 3x ULN , Total bilirubin &gt; 2.0 mg/dL ( 34.2 μmol/L ) , positive serologic evidence current infectious liver disease include Hepatitis B viral antibody IGM , Hepatitis B surface antigen Hepatitis C virus antibody Creatinine Clearance : &lt; 60 mL/min ( calculate CockcroftGault formula ) measure serum creatinine value &gt; 1.5 mg/dL ( 133 μmol/L ) male patient &gt; 1.4 mg/dL ( 124 μmol/L ) female patient , History unstable rapidly progress renal disease History diabetic ketoacidosis ( DKA ) require medical intervention ( eg , emergency room visit and/or hospitalization ) within 1 month prior Screening visit . Volume deplete patient . Recent Cardiovascular Events patient : Acute Coronary Syndrome ( ACS ) within 2 month prior enrolment Hospitalization unstable angina acute myocardial infarction within 2 month prior enrolment Acute Stroke TIA within two month prior enrolment Less two month post coronary artery revascularization Congestive heart failure define New York Heart Association ( NYHA ) class IV , unstable acute congestive heart failure . Treatment insulin , thiazolidinedione ( e.g. , pioglitazone ) , GLP1 agonist , SGLT2 drug may affect plasma glucose level ( include systemic glucocorticoid ) within 3 month prior screen Exclusion criterion healthy control : Clinically ! significant ! abnormality ! ! medical ! history ! ! physical ! examination + smoke regular medication pregnancy , breast feeding tendency towards claustrophobia metal device magnetic material subject body hazardous NMR investigation [ heart pacemaker , brain ( aneurysm ) clip , nerve stimulators , electrode , ear implant , post coronary bypass graft ( epicardial pace wire ) , penile implant , color contact lens , patch deliver medication skin , coil spring intrauterine device , vascular filter blood clot , orthodontic brace , shuntspinal ventricular , metal implant ( rod , joint , plate , pin , screw , nail , clip ) , embolization coil , metal fragment shrapnel body ] . Hepatic insufficiency and/or significant abnormal liver function define aspartate aminotransferase ( AST ) &gt; 3x upper limit normal ( ULN ) and/or alanine aminotransferase ( ALT ) &gt; 3x ULN , Total bilirubin &gt; 2.0 mg/dL ( 34.2 μmol/L ) , positive serologic evidence current infectious liver disease include Hepatitis B viral antibody IGM , Hepatitis B surface antigen Hepatitis C virus antibody Creatinine Clearance : &lt; 60 mL/min ( calculate CockcroftGault formula ) measure serum creatinine value &gt; 1.5 mg/dL ( 133 μmol/L ) male patient &gt; 1.4 mg/dL ( 124 μmol/L ) female patient , History unstable rapidly progress renal disease Volume deplete patient . Patients risk volume depletion due coexisting condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>